Protest at Madrid hospital aims to shame the government into releasing more funds.
19 hours ago | El Pais
U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12-week plan, a bit below its huge selling competitor Sovaldi from Gilead Sciences.
20 hours ago | Reuters
Cigna is monitoring the health outcomes of customers with hepatitis C who have undergone treatment using a prescription combination with the drug Sovaldi. Cigna found that 91.1% of customers achieved a sustained virologic response (SVR). Customers who have an SVR when tested 12 weeks after the completion of treatment are considered cured.
17 December 2014 | Insurance News Net
Gilead has been selling a twelve week regimen of Sovaldi in the United States for approximately $84,000, or $1,000 per pill. This is significantly more than the original price projection for Sovaldi, and in sharp contrast to the prices at which the drug is being made available in other countries. Gilead recently announced its intention to make Sovaldi available in 91 developing countries at deeply discounted prices, and the drug is reportedly available in Egypt for 99% below the U.S. price. This obvious pricing paradox is under investigation by the Senate Finance Committee, which has questioned if the market for Sovaldi “is working efficiently and rationally,” and whether “payors of health care….can carry such a load.”
12 December 2014 | Chimicles & Tikellis press release
Philadelphia's transit agency has sued Gilead Sciences Inc., accusing the company of "price-gouging" on the sale of its $1,000-per-pill hepatitis C drug Sovaldi, the latest salvo in a battle between health-care payers and the pharmaceutical industry.
11 December 2014 | Nasdaq
Later this month, the FDA is expected to approve AbbVie's oral '3-DA' product - comprising Viekirax (ombitasvir/ paritaprevir/ ritonavir) plus Exviera (dasabuvir) - for the treatment of genotype 1 hepatitis C patients. European approval is expected to occur in early 2015 following a positive recommendation from a European Medicines Agency committee last month. Payers in the US are hoping that AbbVie will deliver festive cheer by announcing a notable 'sticker price' discount versus Gilead Sciences' Harvoni brand, which costs $94,500 for a 12-week supply.
10 December 2014 | Hepatitis C New Drugs
Bristol-Myers said the FDA has asked it for data involving use of daclatasvir with other drugs, and that the company is in discussions with the agency about the scope of the required information.
27 November 2014 | Reuters
The maker of Sovriad (simeprevir) has revised its package insert labeling on the order of Japanese health officials following the deaths of three people who took the hepatitis C drug.
24 November 2014 | HCP Live
The fixed price reduced the cost by about 27%, and so a 12-week regimen will now be priced at $51,400, instead of $71,100. This makes this the “lowest price in Europe,” according to the Economic Committee for Health Products. There is also stipulation that rebates will be made in the event of “treatment failure,” according to a statement from the agency.
21 November 2014 | Wall Street Journal
Nice is due to finish its final assessment of sofosbuvir in January. It is usual for them to give the NHS three months to find the money or put staff – if needed – in place. NHS England is thought to have asked them to delay this by six months.
19 November 2014 | Channel 4 News (blog)